Acutus Medical, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2022
January 09, 2023 at 04:30 pm IST
Share
Acutus Medical, Inc. provided revenue guidance for the fourth quarter and full year 2022. For the quarter, the company expected revenue of approximately $4.7-$4.9 million compared to $4.4 million in the fourth quarter of 2021. Year-over-year growth was driven by an increase in commercial AcQMap procedures worldwide, continued adoption of the companyÆs differentiated mapping, therapy and accessory products, and stabilization in capital sales.
For the full year 2022, the company expected revenue to be in a range of $16.1-16.3 million compared to $17.3 million in 2021.
Acutus Medical, Inc. is focused on the production of left-heart access products under its distribution agreement with Medtronic, Inc. (Medtronic). The Company is solely focused on supporting the manufacturing and distribution of products to Medtronic. It manufactures transseptal crossing devices and associated accessories, such as integrated transseptal dilators and needles, fixed-curve or steerable introducers, and steerable sheaths (Products). These Products are used to access the left side, or left atrium, of the cardiac anatomy and are used in a range of medical applications, including in electrophysiology and structural heart procedures. The technology supports physicians during a critical component of an ablation or structural heart procedure. The transseptal crossing devices that it manufactures for Medtronic include versions that are length-, diameter- and tip-matched and designed to lock into the hub of sheaths used in many left-heart procedures.
ACUTUS MEDICAL, INC. 
